Global law firm Freshfields is advising Germany-based pharmaceutical company Grünenthal, a global leader in pain management and research, on its agreement with Bayer AG to acquire the cancer treatment Stivarga® (regorafenib) for up to €375m. The acquisition is subject to customary closing conditions.
Stivarga (regorafenib), which is approved and available in more than 90 markets worldwide, is an oral multikinase inhibitor indicated for metastatic colorectal cancer, hepatocellular carcinoma and gastrointestinal stromal tumours (GIST) in patients who have already been treated with, or who cannot be given, other available treatments. For more information, please see Grünenthal’s press release.
The Freshfields team is working closely again with the Grünenthal inhouse legal M&A team comprising Sebastian Köhler (General Counsel), Maren Müller (Senior Legal Counsel M&A), Ulrike Albus (Head of Trademarks & Senior Counsel Patents) and Sabine König (Senior Legal Counsel).
The Freshfields team comprises:
Lead: Partners Lars Meyer (Frankfurt/Berlin) and Philipp Dohnke (Hamburg), Counsel Philipp Lehmann (Frankfurt), and Principal Associates Vasco Ollero (Hamburg), David Thüning (Berlin) and Maximilian Zellerhoff (Hamburg, all Corporate/M&A and Life Sciences Transactions)
Partners: Ilka Oberländer (Antitrust, Munich), Michael Ramb (Regulatory, Berlin/Düsseldorf), Nina Bayerl (Patents/IP, Munich), Ulrich Sittard (Employment Law, Düsseldorf) and Tanja Walter-Yadegardjam (Tax, Frankfurt)
Counsel: Lukas Pomaroli (Regulatory, Vienna)
Principal Associates: Stephan Reemts (Corporate/M&A, Frankfurt), Flavia Lang (Employment Law, Hamburg), Katharina Reinhardt (Regulatory, Berlin) and Hendrik Menzel (Tax, Frankfurt)
Associates: Johannes Lorber (Berlin), Tainá Moreira de Araújo (Frankfurt, both Corporate/M&A), Asta von Kienitz (Commercial/IP, Hamburg), Fabian Schubach, Diana Baum (both Patents/IP, Munich), Riccardo Fadiga (Brussels), Hanna Hund (Munich, both Antitrust), Tensin Studer (Vienna) and Vinzent Will (both Regulatory, Berlin)
A Freshfields team around Partner Lars Meyer also advised Grünenthal on its acquisition of the testosterone business from Bayer in 2022.